Latest Sofinnova Ventures Stories
Consumer Healthcare Company Focused on Over-the-Counter (OTC) Therapies in Liquid 'Shot' Form to Launch First Products in U.S. in Summer 2013 BURLINGAME, Calif., May 21, 2013 /PRNewswire/ -- First Aid Shot Therapy®, Inc. ("F.A.S.T."), a consumer healthcare company focused on over-the-counter (OTC) therapies in liquid 'shot' (40ml / 1.35oz.) form, today announced it has completed a Series A financing round. New investor Sofinnova Ventures led the round. (Logo:...
Srinivas Akkaraju Joins Sofinnova Ventures as General Partner; Anand Mehra Promoted to General Partner MENLO PARK, Calif., May 2, 2013 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park investment firm, today announced a senior team addition and key promotion. Srinivas Akkaraju, M.D., Ph.D. has joined the firm as General Partner and Anand Mehra, M.D., has been promoted to General Partner. A long-term investor in the life science sector, Dr. Akkaraju will actively invest in...
BRANFORD, Conn., Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. Based in Branford, Connecticut, Marinus is the developer of the first-in-class, neuroactive steroid Ganaxolone. Marinus Pharmaceuticals--the leader in the...
SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition,...
SAINT PETERSBURG, Fla., Dec. 4, 2012 /PRNewswire/ -- Salveo Specialty Pharmacy, Inc., a specialty pharmacy company backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners, today announces the completion of a second round of equity and debt funding, and its subsequent acquisition of Mission Road Pharmacy, a pharmacy based in Los Angeles, California focused on Oncology, HIV/AIDS, Hepatitis, Rheumatoid Arthritis and Mental Health therapies. The additional equity...
LA JOLLA, Calif., Oct. 17, 2012 /PRNewswire/ -- Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, today announced results of a Phase 1/2 trial of its lead investigational drug, ERSATTA(TM) in peripheral neuropathy. ERSATTA is the first once-weekly C-peptide therapy to target loss of nerve function and other vascular complications in type 1 diabetes patients. The successful 72 subject trial, which focused on safety, tolerability, and...
BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners. (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO ) "We believe that SARcode is uniquely positioned to...
RESEARCH TRIANGLE PARK, N.C., March 7, 2011 /PRNewswire/ -- Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners, and existing investors Alta Partners and TPG Biotech. Aerie expects to use proceeds from this financing to fund continued...
MENLO PARK, Calif., Sept. 8 /PRNewswire/ -- Sofinnova Ventures, a venture capital firm based in Silicon Valley, today announced that Garheng Kong, M.D., Ph.D. has joined the firm as General Partner. He will actively invest in biopharmaceutical companies from the firm's current fund, SVP VII. Up until joining Sofinnova, Kong was a General Partner at Intersouth Partners, where he has been for the past ten years. He was the founding investor of Cellective Therapeutics, a Sofinnova Ventures...
BRANFORD, Conn., July 29 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. a developer of drugs to treat serious neurological and psychiatric disorders, today announced the appointment of George F. Horner III of Sofinnova Ventures and Harry T. Rein of Foundation Medical Partners to its Board of Directors. "We are thrilled to expand our board of directors with George and Harry, both of whom have tremendous track records for advancing drug pipelines, leading pharmaceutical and life sciences...
